Project outlinePeople, Organization, Strategy and Technology in the pharmaceutical industryAbstractThe PharmaPOST project is aiming at the investigation and critical analysis of change issues in the pharmaceutical industry. An initial case study during the period Janauary-May 1998 has been conducted at Astra Hässle within NUTEKs CorePoint investigation, and has documented initial findings and outlined a project plan for a longitudinal study. Initially, the implementation of technology for reducing clinical tests' cycle times through RDC (remote data capture) is investigated, together with its impact on organizational and human behaviour. The initial findings will be documented in a report/research paper. BackgroundWithin the pharmaceutical industry, there is an increasing pressure to shorten product development time. One crucial issue in this concern is the conduct of clinical tests and research, i.e. testing and documenting new drugs (CDs - candidate drugs) before submitting an application (NDA - new drug application) to the approving authorities (USA: FDA, Sweden: Läkemedelsverket). This process is both lengthy and costly. In addition, it is conducted within the patent protection period, i.e. a patent for a 20 year priod is granted for a new substance, and all subsequent research and tests are conducted within this period. Thus, every day that can be saved during this process lengthens the patent period during which the company can reap the benefits from the product without competition from producers of generic products. For a successful product, this can mean several billion kroner. In order to improve its operations, a variety of projects has been conducted at Astra Hässle, including organizational restructuring, introduction of new information systems, and more recently a business process oriented project under the name of FASTRAC (Fastest And Smartest To Registration And Commercialization). The project aimed at a complete overhaul of operations within the clinical unit of the company, thus attempting to cut the average time for testing new products by half, from 8 to 4 years. The project outcome was documented and reported to the steering group and company management in 1996. The project report contained a set of 11 recommendation, ranging from technological issues over operating values to structural organizational changes. In 1996, another major change effort was initiated on corporate level (Astra group). This project, termed CANDELA, is dedicated to investigate and analyze business processes on Astra group level and to propose new strategies, structures, processes and technology to be implemented in all Astra companies. The work conducted within this project and its outcome naturally affects Astra Hässle and its processes significantly, and the implementation of measures must be coordinated and aligned between the two projects. PharmaPOST project outlineThe PharmaPOST project, conducted by researchers from the Viktoria Institute in Göteborg, and supported by staff from Astra Hässle, is concerned with following the implementation of measures taken as a consequence of the FASTRAC and CANDELA project. The analysis of these measures and their implementation will identify factors being critical to the success of the conduct of these projects, and generalize the gained knowledge in order to make it accessible for other organizations. Special attention will be paid to the following issues:
Contribution to MTO objectivesThe MTO programme has been designed to address a variety of aspects that allow Swedish companies to sustain or improve their competetive position. In today's competitive environment, this objective is closely related to factors such as knowledge management, innovation and organizational renewal, and the company's ability to employ technology and organizational competencies. Considering the main sectors of the MTO-programme, as being defined in the programme definition statement, they are primarily focusing on three areas, which are essential for competitiveness, namely
While we believe, that these areas can not be separated easily from each other and must be considered holistically, the PharmaPOST project should take its departure in the product and service innovation area. Therefore, the need for product development process innovation will be conceived as the initial driving force, while changes in processes, structures and collaborative patterns are sub-sequent results. Documentation and dissemination of resultsThe project results will primarily be documented as research reports and articles to be published at scientific conferences. Further dissemination activities, in terms of conference participations and seminars, will take place. The members of the research team, as well as Astra Hässle staff are also prepared to participate in events arranged as part of the dissemination activitites within the MTO participant group. |
Project people
BSc/MSc-Thesis
Publications and other writings (in chronological order)
"In the pipeline"
OH-slides (Acrobat PDF-formatted)
Other relevant information and WWW-resources
|
Links |
This page
has been tested with the following browsers:
|